Official launch of full suite of hLAB standalone services Health & Safety Executive (HSE) clearance received for containment level 3 (CL-3) laboratory
hVIVO PLC (AIM:HVO) Interim results – Strong first half delivering record revenues and margins
The exceptional operational delivery across the Group in H1 24 resulted in record revenues of £35.6m, 30.6% higher than H1 2023.
hVIVO PLC (AIM:HVO) Notice of results
hVIVO plc (AIM & Euronext: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that
hVIVO PLC (AIM:HVO) Proposed Cancellation of Admission to Trading on Euronext Growth
hVIVO plc (AIM & Euronext: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces its
hVIVO (AIM:HVO) Trading Update And Capital Markets Day
Octopus Investments recently increased its stake in hVIVO (LON: HVO), which operates the world’s largest commercial human challenge trial unit. The investment group now holds 7.61% of hVIVO’s equity, raising
Timeline Video hVIVO – an extensive history, that dates back to the UK Common Cold Unit in Salisbury
We have an extensive history, that dates back to the UK Common Cold Unit in Salisbury which ran human challenge studies from 1946 until 1989.
hVIVO Broker Endorses Company Following Successful Capital Markets Day
Broker Cavendish reaffirmed its 42p price target for hVIVO PLC (AIM: HVO) stock after a capital markets day (CMD) at the company’s new state-of-the-art quarantine facility in Canary Wharf.
hVIVO PLC (AIM:HVO) Record H1 revenue and EBITDA margin
hVIVO plc (AIM & Euronext: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, provides a
hVIVO PLC (LON:HVO) Capital Markets Event and Trading Update on 17 July
hVIVO plc (AIM & Euronext: HVO), a fast growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that
hVIVO PLC (AIM:HVO) £2.5m contract for Omicron characterisation study
£2.5m Contract for Omicron characterisation study
UK “high likelihood” that the covid virus had leaked from a Chinese lab
During the peak of the Covid pandemic, the US presented Britain with startling evidence indicating a “high likelihood” that the virus had escaped from a laboratory in China, according to
hVIVO PLC (AIM:HVO) positioned for success, according to a US investment bank
In its latest investment research note, Stifel highlights hVIVO PLC’s strong position in the global healthcare market, notably in conducting human challenge clinical trials (HCTs) for infectious and respiratory diseases.